The formation of insoluble protein aggregates is a hallmark
of Huntington's disease (HD) and related neurodegenerative
disorders, such as dentatorubral pallidoluysian
atrophy (DRPLA), spinal bulbar muscular
atrophy (SBMA) and the spinocerebellar ataxia (SCA)
type 1, 2, 3, 6 and 7. These disorders are caused by an
expanded polyglutamine (polyQ) tract in otherwise unrelated
proteins. They are characterized by late-onset,
selective neuropathology, a pathogenic polyQ threshold
and a relationship between polyQ length and disease
progression. Thus, molecular models of HD and
related glutamine-repeat disorders must account for
these characteristic features. During the last three
years, considerable effort has been invested in the
development of
Print ISSN: 1431-6730
Volume: 381, 09/2000
Pages: 937 - 942